Collaboration and Licensing Revenue (Tables)

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenue

The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the three and nine months ended September 30, 2015 and 2014.

	Three Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	645	$	4,006	$	4,651
Oragenics, Inc.	4,868		332		5,200
Fibrocell Science, Inc.	4,823		1,317		6,140
Genopaver, LLC	68		993		1,061
S & I Ophthalmic, LLC	—		1,193		1,193
OvaXon, LLC	—		549		549
Intrexon Energy Partners, LLC	625		3,185		3,810
Persea Bio, LLC	125		297		422
Ares Trading S.A.	1,597		260		1,857
Other	7,841		2,002		9,843
Total	$	20,592	$	14,134	$	34,726

	Three Months Ended September 30, 2014
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	644	$	3,370	$	4,014
Oragenics, Inc.	261		3		264
Fibrocell Science, Inc.	449		1,014		1,463
Genopaver, LLC	68		360		428
S & I Ophthalmic, LLC	—		667		667
OvaXon, LLC	—		813		813
Intrexon Energy Partners, LLC	625		1,535		2,160
Other	443		2,404		2,847
Total	$	2,490	$	10,166	$	12,656

	Nine Months Ended September 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,933	$	11,769	$	13,702
Oragenics, Inc.	5,437		408		5,845
Fibrocell Science, Inc.	5,719		4,500		10,219
Genopaver, LLC	205		2,460		2,665
S & I Ophthalmic, LLC	—		2,838		2,838
OvaXon, LLC	—		1,855		1,855
Intrexon Energy Partners, LLC	1,875		8,101		9,976
Persea Bio, LLC	375		553		928
Ares Trading S.A.	2,336		260		2,596
Other	9,446		6,620		16,066
Total	$	27,326	$	39,364	$	66,690

	Nine Months Ended September 30, 2014
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,932	$	9,103	$	11,035
Oragenics, Inc.	784		588		1,372
Fibrocell Science, Inc.	1,345		2,759		4,104
Genopaver, LLC	205		1,204		1,409
S & I Ophthalmic, LLC	—		2,153		2,153
OvaXon, LLC	—		1,561		1,561
Intrexon Energy Partners, LLC	1,250		2,745		3,995
Other	1,373		5,255		6,628
Total	$	6,889	$	25,368	$	32,257

Summary of Deferred Revenue

Deferred revenue consists of the following:

	September 30, 2015		December 31, 2014
Upfront and milestone payments	$	159,069	$	107,228
Prepaid research and development services	11,099		1,045
Prepaid product and service revenues	5,292		4,365
Other	794		571
Total	$	176,254	$	113,209
Current portion of deferred revenue	$	32,006	$	16,522
Long-term portion of deferred revenue	144,248		96,687
Total	$	176,254	$	113,209